Ilka Wicke
Direktor/Vorstandsmitglied bei Pcovery ApS
Profil
Ilka Wicke is an Investment Manager & Director at Boehringer Ingelheim (Venture Capital) since 2010.
She is also a Director at Pcovery ApS.
Previously, she worked as a Licensing Director at Boehringer Ingelheim GmbH, and as a Director at PROMETHERA Biosciences SA, Cardior Pharmaceuticals GmbH, and AgomAb Therapeutics NV.
Dr. Wicke holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Aktive Positionen von Ilka Wicke
Unternehmen | Position | Beginn |
---|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Private Equity Investor | 01.01.2010 |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Ilka Wicke
Unternehmen | Position | Ende |
---|---|---|
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Direktor/Vorstandsmitglied | 06.04.2018 |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Direktor/Vorstandsmitglied | - |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Direktor/Vorstandsmitglied | - |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | - |
Ausbildung von Ilka Wicke
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Finance |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Commercial Services |